BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Odyssey Thera, Inc. Announces U.S. Patent for Technologies Enabling Protein Interaction Screening and Directed Evolution


1/5/2011 6:24:38 AM

SAN RAMON, Calif., Jan. 5, 2011 /PRNewswire/ -- Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167. The invention describes technologies and high-throughput methods for identifying bimolecular interactions in vivo based on protein-fragment complementation assays (PCA). The patent, the eighteenth assigned to Odyssey Thera, further protects assays utilizing fragments of inherently fluorescent proteins, and the use of these assays for high-throughput screening of defined panels of proteins. The strategy is applicable in any cell type and using a wide range of reporters and detection methods. The invention enables identification and validation of genes and proteins involved in any cellular process, and also provides assays to study the effects drugs and gene expression or knockout on specific pathways.

"This patent significantly extends the reach of Odyssey Thera's technology platform," said John K. Westwick, Ph.D., Odyssey Thera President and CEO. "The assays and their use in gene vs. library and library vs. library screening provide a uniquely powerful strategy for biotherapeutic identification and optimization, diagnostic and biomarker development, the discovery of genetic modifiers of animal and plant cell traits, and bioprocess engineering."

About Odyssey Thera

Odyssey Thera, Inc. is a technology company committed to developing breakthroughs in cellular analysis and engineering. Odyssey Thera's technologies measure pathway activity within living cells, and are applicable to therapeutic discovery and development, engineering of any cell type or species, live animal imaging, and diagnostic and bioprocess applications. To learn more about Odyssey Thera, please visit www.odysseythera.com.

SOURCE Odyssey Thera, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES